{
    "2021-12-15": [
        [
            {
                "time": "",
                "original_text": "健帆生物：对公司血液灌流器产品，我们预判在短期内不会被纳入全国性集中带量采购范围",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "血液灌流器",
                        "短期",
                        "全国性集中带量采购"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：公司血液透析器产品注册证在申报中，预计明年取得",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "血液透析器",
                        "注册证",
                        "申报",
                        "明年"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}